Clinical Oncology

The Medical University of South Carolina and Flatiron Health Announce Collaboration to Drive More Standardized, Efficient, and Effective Cancer Care

Retrieved on: 
Wednesday, March 13, 2024
Research, Technology, Clinical Trials, Health Technology, University, Health, Science, Education, Oncology, Artificial Intelligence, Evidence-based medicine, Associate, Patient, NCCN, Assist, MD, MHS, Medical school, Flatiron, MUSC, Division, Clinical Oncology, Hematology, Medicine, Nursing

The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care.

Key Points: 
  • The collaboration between Flatiron Health and MUSC will equip clinicians with advanced cancer care insights from Flatiron Assist, an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways, and clinical research at the point of care.
  • “Partnering with the Medical University of South Carolina’s Hollings Cancer Center, a market-leading cancer care provider, is an incredible opportunity to accelerate our shared vision for the delivery of more standardized, efficient, and effective cancer care,” said James Hamrick, MD, Vice President of Clinical Oncology at Flatiron Health.
  • Flatiron Assist users also adopt novel therapies an average of 59 days sooner than non-Flatiron Assist users ensuring higher quality care.
  • “This project will reduce variability in cancer treatment while increasing the quality of cancer care provided across the state of South Carolina.”

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Retrieved on: 
Monday, October 30, 2023
American Society of Clinical Oncology, TILS, Principal, New York University Grossman School of Medicine, NCI, Rockefeller University, Clinical Oncology, Research, TIL, Centers of Biomedical Research Excellence, NYU, Selection, Melanoma, National Cancer Institute, PCC, Patient, Veteran, SAB, SPORE, Skin cancer, SAN, United States Air Force Scientific Advisory Board, Pharmaceutical industry, Medical imaging, Turnstone, Medicine

“We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone.

Key Points: 
  • “We are very pleased to welcome Dr. Weber to the Turnstone Scientific Advisory Board,” said Stewart Abbot, Ph.D., Turnstone.
  • Weber’s work has led to groundbreaking achievements in cancer immunotherapy, and he brings unique expertise and perspective to our SAB.
  • “Turnstone is advancing a differentiated approach to TIL therapy and I am delighted to join the esteemed members of Turnstone’s SAB,” said Dr. Weber.
  • I look forward to partnering with Turnstone to deliver the next-generation of TIL therapies to underserved patient populations.”

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Association of American Physicians, Faculty, American College, ASCO, Dean, MD Anderson Cancer Center, Vice, Clinical professor, Hematology, American Society of Clinical Oncology, Advisory board, University of Nebraska Medical Center, Department of Medicine – University of Pamplona, Clinical Oncology, Society, Internal medicine, UNMC, College, Membership of the Royal College of Physicians of Ireland, Royal college, Nebraska Medicine, Division, Richard, University, American College of Physicians, Mayo Clinic, Cancer, Patient, American Association for Cancer Research, Transplant, Book, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Nursing, Medical device, Physician

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform

Retrieved on: 
Tuesday, October 31, 2023
Technology, Genetics, Health Technology, Software, Practice Management, Biotechnology, Health, Data Management, Oncology, Artificial Intelligence, Flatiron, MPH, Physician, Clinical Oncology, Research, Helmy Eltoukhy, Multimedia, GH, Recurrence, EMR, Cancer, Patient, Molecule, Medical imaging, Nursing, MD

“Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, Guardant Health chief commercial officer.

Key Points: 
  • “Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, Guardant Health chief commercial officer.
  • Guardant Health and Flatiron Health plan to roll the integration out to the entire OncoEMR network over the next several months.
  • Practices in the network will have access to Guardant Health’s entire portfolio of advanced blood and tissue tests for early- and advanced-stage cancer through the Molecular Profiling Integration.
  • “By offering integrated test ordering and reporting for Guardant Health’s genomic profiling tests within OncoEMR, we are enabling oncologists with the tools they need to further expand possibilities at the point of care," said James Hamrick, MD, MPH, Vice President, Clinical Oncology at Flatiron Health.

Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Aurora, Histology, Chinese University of Hong Kong, Multimedia, Science, Lung cancer, Biomarker, Chinese, University, Cedars-Sinai Medical Center, CLDN1, Abstract, Lung transplantation, The New England Journal of Medicine, AACR, Anesthesiology, Clinical Oncology, Clarivate, Long Island Jewish Medical Center, Book, Coronavirus Scientific Advisory Board, IPF, Respiratory therapist, University of the Witwatersrand School of Chemical and Metallurgical Engineering, Food and Drug Administration, Lung, US Food Sovereignty Alliance, Medical director, Patient, Idiopathic pulmonary fibrosis, AstraZeneca, ESMO, Therapy, Article, Publication, Long Island, ASCO, Pulmonary hypertension, CSCO, Research, Inova Fairfax Hospital, Pharmaceutical industry, Medical device, Vaccine

Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.

Key Points: 
  • Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20231005193827/en/
    Lung experts Prof. Steven Nathan and Prof. Tony Mok join Alentis Therapeutics' Scientific Advisory Board.
  • (Photo: Alentis Therapeutics)
    “Tony and Steven have exceptional expertise in lung cancer and lung fibrosis, respectively, which will be of great value to our Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.
  • Prof. Steven Nathan is the Medical Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and is a Professor at the University of Virginia.

Flatiron Health to Be a Featured Presenter at the 2023 Clinical Pathways Congress + Cancer Care Business Exchange

Retrieved on: 
Wednesday, September 27, 2023
Technology, Managed Care, Professional Services, Hospitals, Science, Genetics, Data Analytics, Clinical Trials, FDA, Biotechnology, Health, Health Technology, Research, Other Health, Pharmaceutical, Artificial Intelligence, Oncology, FRCP, CGC, Barrier, FACP, Personalized medicine, Cancer, Booth, Clinical Oncology, Doctor of Philosophy, Congress, Journal, Community, Patient, Memorial Sloan Kettering Cancer Center, Medicine, Flatiron, MPH, HMP, Duke, Pharmaceutical industry, Nursing, Medical device, Hospital, Birth control, MD

Flatiron Health is presenting multiple sessions at HMP Global’s Clinical Pathways Congress + Cancer Care Business Exchange, advancing the conversation among stakeholders who have interest, influence, and impact on the evolving business models and delivery of cancer care, with a focus on improving outcomes for patients.

Key Points: 
  • Flatiron Health is presenting multiple sessions at HMP Global’s Clinical Pathways Congress + Cancer Care Business Exchange, advancing the conversation among stakeholders who have interest, influence, and impact on the evolving business models and delivery of cancer care, with a focus on improving outcomes for patients.
  • The 2023 Congress will be held October 6-8 in Boston and is the official meeting of the Journal of Clinical Pathways, a peer-reviewed journal that works to advance the discussion of clinical pathways to provide high-quality, cost-effective care.
  • “At Flatiron we strive to elevate clinical care by delivering point-of-care technology solutions that serve doctors and patients within their busy workflows,” said James Hamrick, Flatiron’s VP of Clinical Oncology.
  • Follow Flatiron Health on Twitter and LinkedIn for live updates from the Clinical Pathways Congress and visit us in person at Booth #200.

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

Retrieved on: 
Friday, April 21, 2023
Drug development, University, CMC, Cancer, Hope, Nebraska Medicine, University of Nebraska Medical Center, Infection, Dove Medical Press, Clinical Oncology, CMO, Bayer, Medical director, Patient, Corporation, Fudan University, Motivation, Global Medical Device Nomenclature, Growth, Therapy, Shanghai Medical College, Pharmaceutical industry, Medical device, Science

SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).

Key Points: 
  • SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).
  • Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall corporate strategy planning and implementation.
  • Dr. Kong holds a doctor's degree from Shanghai Medical College of Fudan University and a master's degree of Science in Molecular Immunology from University of Nebraska Medical Center.
  • Before joining ImmVira, he served as Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, Vice President of Clinical Oncology at Hengrui Therapeutics, Senior Global Medical Leader of Global Medical Affairs at Novartis Oncology, Senior Medical Director at Celegene and Medical Director of US Medical Affairs at Bayer HealthCare Pharmaceuticals.

Flamingo Therapeutics Announces Appointment of Andrew E. Denker, MD, PhD, as Chief Medical Officer

Retrieved on: 
Tuesday, April 4, 2023
STAT3, Therapy, Thomas Jefferson University, Clinical trial, Cancer, Head, Clinical Oncology, RNA, Princeton University, Alexion Pharmaceuticals, Patient, Patent, Washington University School of Medicine, Washington University School of Law, Growth, Merck Sharp & Dohme Federal Credit Union, General surgery, Pharmaceutical industry, Flamingo, MD

LEUVEN, Belgium, STRASBOURG, France, and PHILADELPHIA, April 4, 2023 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the appointment of Andrew E. Denker, MD, PhD., as Chief Medical Officer.

Key Points: 
  • LEUVEN, Belgium, STRASBOURG, France, and PHILADELPHIA, April 4, 2023 /PRNewswire/ -- Flamingo Therapeutics ("Flamingo") today announced the appointment of Andrew E. Denker, MD, PhD., as Chief Medical Officer.
  • In his new role, Dr. Denker will be responsible for leading and expanding Flamingo's clinical portfolio and will serve as a key member of its executive leadership team.
  • The company's deep expertise in RNA therapeutics and oncology development, coupled with its outstanding team and partners, make this a compelling opportunity for me.
  • I look forward to working with the team and board to advance Flamingo's clinical portfolio and improve the lives of patients with cancer."

Caris Life Sciences and Flatiron Health Partner to Vastly Increase Access to Most Comprehensive Molecular Testing Available

Retrieved on: 
Friday, September 23, 2022
Workflow, Precision medicine, Policy, Twitter, American Securities, Association of British HealthTech Industries, Hoffmann-La Roche, Blood, Health, Partnership, Environment, Patient, Cancer, Physician, Clinical Oncology, MBA, Protein, Exome, EMR, Molecule, Diagnosis, Artificial intelligence, Drug development, RNA, Research, DNA, Data science, Flatiron, Education, Oncology, Disease, Pharmaceutical industry, Medical imaging

IRVING, Texas, Sept. 23, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a partnership with Flatiron Health, a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients, to integrate Caris' market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record (EMR) tool.

Key Points: 
  • Through the Molecular Profiling Integration, users can easily submit Caris orders with fewer clicks and less data entry, track real-time status updates, and receive the results directly within OncoEMR.
  • This streamlines clinical workflows for physicians and offers access to Caris molecular reports in the same environment in which they develop care plans.
  • Caris' entire suite of molecular profile services, including comprehensive whole exome and whole transcriptome sequencing, is now available for ordering within the OncoEMR network.
  • Caris Life Sciences(Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes.

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

Retrieved on: 
Wednesday, September 21, 2022
Safety, Bevacizumab, Memory, Engineering, Woman, CI, Recurrence, Ovarian cancer, Vaccinia, Vagina, Company, Medicine, United, Clinical Ovarian Cancer & Other Gynecologic Malignancies, GOG, SEER, Immunotherapy, Survival, Vulva, Patient, Cancer, NCI, Clinical Oncology, CEO, Urogenital pelvic malignancy, ORR, Progression-free survival, Uterus, Neoplasm, Method, Death, Research, Abdominal pain, GLOBE, DNA, Disease, RECIST, Immunogenic cell death, Pharmaceutical industry, Birth control, Vaccine, Genelux Corporation, Gynecologic Oncology (journal), Epidemiology

Initiating the OnPrime trial represents a major milestone for Genelux, saidThomas D. Zindrick, President and CEO, Genelux.

Key Points: 
  • Initiating the OnPrime trial represents a major milestone for Genelux, saidThomas D. Zindrick, President and CEO, Genelux.
  • Our goal in Phase 3 is to replicate these positive results and transform the treatment paradigm for this particularly difficult-to-treat cancer.
  • We look forward to progressing our study and sharing updates on the Olvi-Vec clinical development program.
  • Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer.